Biomedino filed suit on Jan. 7 with the US District Court for the Western District of Washington,
The patent, granted to Meir Strahilevitz, the sole inventor, in August 2003 and licensed to Biomedino, covers immunoassays of psychoactive drugs and treatment methods, based on the antigenic properties of protein conjugates of these drugs.
Biomedino said in its complaint that several chromatography-based separations systems made by the three plaintiffs infringe its patents. The company is seeking damages from all three "which in no event can be less than a reasonable royalty."
An Agilent spokesperson said the company has not yet been served with the suit. Officials from GE Healthcare and Waters did not immediately return a telephone call seeking comment.